F03-50 ID-CAR-T

F03-50 ID-CAR-T is a chimeric antigen receptor T cell (CAR-T) therapy. CAR-T therapies are advanced cellular immunotherapies in which a patient's or donor's T cells are genetically engineered to express synthetic receptors (CARs) that target specific antigens on cancer cells. These modified T cells are then expanded and infused back into the patient, where they seek out and destroy malignant cells expressing the target antigen. CAR-T therapies have shown curative potential for relapsed or refractory hematologic malignancies, particularly large B-cell lymphomas[1][3]. The specific details regarding the target antigen, developer, and clinical status of F03-50 ID-CAR-T could not be found in available sources.